



## **NEUPATH HEALTH TO PRESENT AT THE 2023 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE**

**TORONTO, ONTARIO, April 18, 2023** – NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced that Joseph Walewicz, CEO, will be presenting at the 2023 Bloom Burton & Co. Healthcare Investor Conference.

Date: Wednesday, April 26, 2023

Time: 4:00 p.m. ET

Format: 30-minute live virtual presentation, including Q&A

To register for the presentation, please visit the Investors section of our website at: <https://www.neupath.com/investors/decks-presentations>. A replay of the webcast will remain available for 90 days following the presentation.

### **About the Conference**

The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.

### **About NeuPath**

NeuPath operates a network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. We operate a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. NeuPath is focused on enabling each individual we treat to live their best life.

### **For more information, please contact:**

Jeff Zygouras  
Chief Financial Officer  
[info@neupath.com](mailto:info@neupath.com)  
(905) 858-1368

*NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS THE RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.*